Literature DB >> 6202715

Diversity of autoantibodies in avian scleroderma. An inherited fibrotic disease of White Leghorn chickens.

D C Haynes, M E Gershwin.   

Abstract

University of California, Davis line 200 White Leghorn chickens develop an inherited progressive fibrotic disease that includes the appearance of antinuclear antibodies (ANA). To further characterize these ANA, serial aged line 200 birds were studied. Greater than 50% of line 200 birds develop antinuclear and anticytoplasmic antibodies; fluorescent staining patterns included cytoplasmic spider web, most prevalent at 1 mo of age, and fine speckled patterns, characteristic of chickens 6 mo and older. By enzyme-linked immunosorbent assay, 40.4% of line 200 birds were found to have antibodies to single-stranded DNA (ssDNA). In contrast, antibodies to histones, RNA, or poly A . poly U were not detected. Precipitating antibodies to saline extracts from chicken liver were noted in 33.3% of line 200 birds. Saline extracts from turkey, pheasant, and partridge liver but not rat, rabbit, or mouse tissues were also positive in immunodiffusion testing with these line 200 birds. The antigenicity of chicken liver extracts was sensitive to pronase, protease K. and pH variations greater than 10 and less than 5; however, they were resistant to trypsin. DNase. RNase, and incubation at 37 degrees C and 56 degrees C for 1 h. Cell fractionation in conjunction with column chromatographic techniques revealed that several protein antigens with apparent molecular weights in the range of 62,000-290,000 were present in cytoplasm but not in isolated nuclei. Line 200 sera were not reactive against nuclear ribonucleoprotein, Sm, Scl-70, or SS-B/La antigens. Thus, line 200 chickens develop antinuclear and anticytoplasmic antibodies at an early age, which recognize a unique group of protein antigenic determinants found only in avian species. Moreover, and of particular interest, the presence of autoantibodies to saline-extractable antigens correlated with positive ANA, antibodies in ssDNA, and to the clinical expression of disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202715      PMCID: PMC437066          DOI: 10.1172/JCI111362

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  Anti-cytoplasmic factors in the sera of patients with systemic lupus erythematosus and certain other diseases.

Authors:  H R DEICHER; H R HOLMAN; H G KUNKEL
Journal:  Arthritis Rheum       Date:  1960-02

2.  Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera.

Authors:  M Mattioli; M Reichlin
Journal:  J Immunol       Date:  1971-11       Impact factor: 5.422

3.  Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythmatosus.

Authors:  G Clark; M Reichlin; T B Tomasi
Journal:  J Immunol       Date:  1969-01       Impact factor: 5.422

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications.

Authors:  D Doniach; I M Roitt; J G Walker; S Sherlock
Journal:  Clin Exp Immunol       Date:  1966-07       Impact factor: 4.330

6.  Cytoplasmic antibodies in patients with systemic lupus erythematosus.

Authors:  G Wiedermann; P A Miescher
Journal:  Ann N Y Acad Sci       Date:  1965-06-30       Impact factor: 5.691

7.  Heterogeneity of RNA protein antigens reactive with sera of patients with systemic lupus erythematosus. Description of a cytoplasmic nonribosomal antigen.

Authors:  M Mattioli; M Reichlin
Journal:  Arthritis Rheum       Date:  1974 Jul-Aug

8.  Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA).

Authors:  G C Sharp; W S Irvin; E M Tan; R G Gould; H R Holman
Journal:  Am J Med       Date:  1972-02       Impact factor: 4.965

9.  Antibodies to ribosomal ribonucleic acid (rRNA) in patients with systemic lupus erythematosus (SLE).

Authors:  E W Lamon; J C Bennett
Journal:  Immunology       Date:  1970-09       Impact factor: 7.397

10.  Antibodies to polynucleotides in human sera: antigenic specificity and relation to disease.

Authors:  D Koffler; R Carr; V Agnello; R Thoburn; H G Kunkel
Journal:  J Exp Med       Date:  1971-07-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Animal models for scleroderma: an update.

Authors:  Yan Zhang; Anita C Gilliam
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

2.  Altered procollagen mRNA expression during the progression of avian scleroderma.

Authors:  M J Ausserlechner; R Sgonc; H Dietrich; G Wick
Journal:  Mol Med       Date:  1997-10       Impact factor: 6.354

3.  Animal model of human disease. Avian scleroderma. An inherited fibrotic disease of white Leghorn chickens resembling progressive systemic sclerosis.

Authors:  J van de Water; M E Gershwin
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

Review 4.  Pathogenic mechanisms of anti-endothelial cell antibodies (AECA): their prevalence and clinical relevance.

Authors:  Cristiano Alessandri; Michele Bombardieri; Guido Valesini
Journal:  Adv Clin Chem       Date:  2006       Impact factor: 5.394

Review 5.  Avian models with spontaneous autoimmune diseases.

Authors:  Georg Wick; Leif Andersson; Karel Hala; M Eric Gershwin; Carlo Selmi; Gisela F Erf; Susan J Lamont; Roswitha Sgonc
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.